This company listing is no longer active
IDOGEN Stock Overview
Idogen AB (publ), a biotechnology company, develops tolerogenic cell therapies to prevent the patient’s immune system from attacking biological agents, transplanted organs, and the body’s own cells or tissues in Sweden.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Idogen AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.12 |
| 52 Week High | kr0.55 |
| 52 Week Low | kr0.015 |
| Beta | 1.78 |
| 1 Month Change | -20.20% |
| 3 Month Change | 41.76% |
| 1 Year Change | -62.92% |
| 3 Year Change | -98.22% |
| 5 Year Change | -99.58% |
| Change since IPO | -99.82% |
Recent News & Updates
Recent updates
Shareholder Returns
| IDOGEN | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -5.5% | 2.4% | 0.7% |
| 1Y | -62.9% | -0.5% | 1.7% |
Return vs Industry: IDOGEN underperformed the Swedish Biotechs industry which returned -6.6% over the past year.
Return vs Market: IDOGEN underperformed the Swedish Market which returned 4.4% over the past year.
Price Volatility
| IDOGEN volatility | |
|---|---|
| IDOGEN Average Weekly Movement | 194.5% |
| Biotechs Industry Average Movement | 9.2% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in SE Market | 13.1% |
| 10% least volatile stocks in SE Market | 3.9% |
Stable Share Price: IDOGEN is more volatile than 90% of Swedish stocks over the past 3 months, typically moving +/- 87% a day.
Volatility Over Time: IDOGEN's weekly volatility has increased from 95% to 194% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 6 | Christina Herder | https://www.idogen.com |
Idogen AB (publ), a biotechnology company, develops tolerogenic cell therapies to prevent the patient’s immune system from attacking biological agents, transplanted organs, and the body’s own cells or tissues in Sweden. The company’s advanced product candidate is IDO 8 that is designed for patients with severe haemophilia A, who have developed neutralizing antibodies against critical treatment with coagulation factor VIII. It also develops IDO T, a tolerogenic cell therapy to prevent organ transplant rejection primarily kidney transplantation; and IDO AID for the treatment of autoimmune diseases.
Idogen AB (publ) Fundamentals Summary
| IDOGEN fundamental statistics | |
|---|---|
| Market Cap | kr12.58m |
| Earnings (TTM) | -kr44.05m |
| Revenue (TTM) | kr771.00k |
16.3x
P/S Ratio-0.3x
P/E RatioIs IDOGEN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IDOGEN income statement (TTM) | |
|---|---|
| Revenue | kr771.00k |
| Cost of Revenue | kr0 |
| Gross Profit | kr771.00k |
| Other Expenses | kr44.82m |
| Earnings | -kr44.05m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
Aug 23, 2023
| Earnings per share (EPS) | -0.42 |
| Gross Margin | 100.00% |
| Net Profit Margin | -5,712.97% |
| Debt/Equity Ratio | 0% |
How did IDOGEN perform over the long term?
See historical performance and comparison